Upstream Bio (UPB) Common Equity (2023 - 2026)

Upstream Bio has reported Common Equity for 4 years, with the latest figure at $304.0 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 31.78% year-over-year to $304.0 million; the trailing twelve-month figure through Mar 2026 stood at $304.0 million (down 31.78% YoY), and the FY2025 full-year result was $339.8 million, down 27.69% from the prior year.
• Common Equity for Q1 2026 stood at $304.0 million, down from $339.8 million in the prior quarter.
• The five-year high for Common Equity was $469.9 million in Q4 2024, with the low at -$160.3 million in Q3 2024.
• Average Common Equity over 4 years is $151.9 million, with a median of $304.0 million recorded in 2026.
• Peak annual rise in Common Equity reached 481.6% in 2024, while the deepest fall reached 42.87% in 2024.
• Tracing UPB's Common Equity over 4 years: stood at -$123.1 million in 2023, then surged by 481.6% to $469.9 million in 2024, then declined by 27.69% to $339.8 million in 2025, then declined by 10.53% to $304.0 million in 2026.
• The last three Common Equity figures came in at $304.0 million (Q1 2026), $339.8 million (Q4 2025), and $378.6 million (Q3 2025), per Business Quant data.

Peer Comparison